Anthrax meningitis
ICD-10 A22.1 is a billable code used to indicate a diagnosis of anthrax meningitis.
Anthrax meningitis is a severe and rare form of meningitis caused by the bacterium Bacillus anthracis, which is primarily associated with zoonotic infections. This condition arises when anthrax spores enter the central nervous system, often following a systemic infection that can originate from cutaneous, gastrointestinal, or inhalational routes. The clinical presentation may include fever, headache, neck stiffness, altered mental status, and other neurological deficits. Diagnosis is typically confirmed through cerebrospinal fluid analysis, which may reveal pleocytosis, elevated protein levels, and the presence of anthrax bacilli. Given its potential for rapid progression and high mortality rate, prompt recognition and treatment are critical. Public health considerations are paramount, as anthrax is classified as a potential bioterrorism agent, necessitating surveillance and preparedness measures in healthcare settings. Vaccination and prophylactic antibiotics are recommended for individuals at high risk of exposure, particularly in endemic areas or during outbreaks.
Detailed patient history, exposure risks, and laboratory results.
Patients presenting with fever and neurological symptoms after known exposure to anthrax.
Need for thorough documentation of diagnostic tests and treatment protocols.
Neurological examination findings and imaging results.
Patients with altered mental status and signs of meningitis.
Documentation must clearly differentiate between types of meningitis.
Used when confirming the presence of Bacillus anthracis.
Document the source of the culture and clinical indications.
Infectious disease specialists should ensure thorough documentation of clinical context.
Common symptoms include fever, severe headache, neck stiffness, altered mental status, and neurological deficits. Prompt recognition is crucial for effective treatment.
